JP Morgan Chase
IMDX

JP Morgan Chase’s Insight Molecular Diagnostics IMDX Stock Holding History

JP Morgan Chase’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393 Hold
154
– – ﹤0.01% 7200
2025
Q4 		$1.16K Hold
154
– – ﹤0.01% 7010
2025
Q3 		$511 Hold
154
– – ﹤0.01% 7048
2025
Q2 		$465 Sell
154
-14
-8% -$42 ﹤0.01% 6704
2025
Q1 		$514 Sell
168
-27
-14% -$73 ﹤0.01% 6700
2024
Q4 		$465 Buy
195
+41
+27% +$111 ﹤0.01% 6811
2024
Q3 		$439 Hold
154
– – ﹤0.01% 6814
2024
Q2 		$454 Hold
154
– – ﹤0.01% 6697
2024
Q1 		$451 Hold
154
– – ﹤0.01% 6734
2023
Q4 		$382 Hold
154
– – ﹤0.01% 6959
2023
Q3 		$505 Sell
154
-1
-0.6% -$4 ﹤0.01% 6727
2023
Q2 		$714 Hold
155
– – ﹤0.01% 6503
2023
Q1 		$1K Hold
155
– – ﹤0.01% 6536
2022
Q4 		$1K Sell
155
-235
-60% -$2.59K ﹤0.01% 6426
2022
Q3 		$6K Buy
390
+72
+23% +$1.25K ﹤0.01% 6067
2022
Q2 		$6K Sell
318
-1,678
-84% -$38.2K ﹤0.01% 6125
2022
Q1 		$59K Buy
1,996
+400
+25% +$12.8K ﹤0.01% 5728
2021
Q4 		$69K Buy
1,596
+406
+34% +$23.4K ﹤0.01% 5823
2021
Q3 		$85K Sell
1,190
-2,036
-63% -$187K ﹤0.01% 5647
2021
Q2 		$370K Sell
3,226
-3,086
-49% -$301K ﹤0.01% 4885
2021
Q1 		$655K Buy
6,312
+1,243
+25% +$118K ﹤0.01% 4509
2020
Q4 		$243K Buy
5,069
+2,655
+110% +$97.4K ﹤0.01% 4739
2020
Q3 		$69K Buy
2,414
+571
+31% +$16.4K ﹤0.01% 4842
2020
Q2 		$71K Sell
1,843
-2
-0.1% -$103 ﹤0.01% 4692
2020
Q1 		$91K Buy
1,845
+446
+32% +$21.9K ﹤0.01% 4547
2019
Q4 		$63K Buy
1,399
+921
+193% +$33.2K ﹤0.01% 5047
2019
Q3 		$20K Buy
478
+183
+62% +$7.19K ﹤0.01% 5411
2019
Q2 		$15K Sell
295
-1,994
-87% -$166K ﹤0.01% 5497
2019
Q1 		$181K Buy
2,289
+2,274
+15,160% +$147K ﹤0.01% 4664
2018
Q4 		$0 Hold
15
– – ﹤0.01% 5851
2018
Q3 		$1K Hold
15
– – ﹤0.01% 5638
2018
Q2 		$1K Sell
15
-23
-61% -$1.13K ﹤0.01% 5490
2018
Q1 		$2K Sell
38
-15
-28% -$991 ﹤0.01% 5290
2017
Q4 		$5K Buy
+53
New +$5.97K ﹤0.01% 5320
2017
Q2 		– Sell
-2
Closed – – 5137
2017
Q1 		$0 Hold
2
– – ﹤0.01% 5178
2016
Q4 		$0 Buy
+2
New +$220 ﹤0.01% 5095

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's IMDX Position: Q1 2026 in Review

JP Morgan Chase held its Insight Molecular Diagnostics (IMDX) position steady in Q1 2026 at 154 shares worth $393. The position accounts for ﹤0.01% of the portfolio, ranked #7200.

JP Morgan Chase first reported a position in IMDX in Q4 2016 and has held it in 36 quarters since. The position peaked at $655K in Q1 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • JP Morgan Chase held 154 shares of Insight Molecular Diagnostics worth $393 as of Q1 2026.
  • JP Morgan Chase left its Insight Molecular Diagnostics share count unchanged in Q1 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7200 holding.
  • JP Morgan Chase first reported a position in Insight Molecular Diagnostics in Q4 2016 and has held it in 36 quarters since.
  • JP Morgan Chase's Insight Molecular Diagnostics position peaked at $655K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.